Healthcare, Financials Jun 26, 2022 08:44 PM (GMT+8) · EqualOcean
Haichuang pharmaceutical announced that recently, the multi center, randomized, double-blind, placebo-controlled phase III clinical trial of denlumide (hc-1119) independently developed by the company for the treatment of metastatic castration resistant prostate cancer (mcrpc) has completed the preset interim analysis. After reviewing the results, the independent data monitoring committee determined that the trial reached the preset primary research endpoint. The company will submit the pre marketing communication application to the drug evaluation center of the State Food and Drug Administration in the near future.